論文 - 詳細
| RRC ID | 52542 |
|---|---|
| 著者 | Imamura T, Komatsu S, Ichikawa D, Miyamae M, Okajima W, Ohashi T, Kiuchi J, Nishibeppu K, Kosuga T, Konishi H, Shiozaki A, Okamoto K, Fujiwara H, Otsuji E. |
| タイトル | Low plasma levels of miR-101 are associated with tumor progression in gastric cancer. |
| ジャーナル | Oncotarget |
| Abstract |
Background:Several studies have identified the decreased expression of the tumor suppressor miR-101 in various cancers. In this study, we tested miR-101 as a potential therapeutic target and novel plasma biomarker for gastric cancer (GC). Results:The miR-101 expression level was significantly lower in GC tissues (P = 0.0038) and GC cell lines (P = 0.0238) than in normal gastric mucosa. Both exosomal and plasma miR-101 were significantly downregulated in GC patients compared with healthy volunteers (P = 0.0281 and P < 0.0001, respectively). Low miR-101 plasma level was significantly associated with advanced T factor, advanced disease stage, and peritoneal metastasis and predicted poor prognosis in GC patients (P = 0.0368; hazard ratio, 3.079; 95% confidence interval: 1.06-11.08). Overexpression of miR-101 in GC cells induced apoptosis by inhibiting MCL1 and suppressed cell migration and invasion by regulating ZEB1. Conclusions:Depletion of the tumor suppressor miRNA-101 in plasma is related to tumor progression and poor outcomes. Low plasma miR-101 may be a biomarker for GC, and its restoration might be a novel anticancer treatment strategy. |
| 巻・号 | 8(63) |
| ページ | 106538-106550 |
| 公開日 | 2017-12-5 |
| DOI | 10.18632/oncotarget.20860 |
| PII | 20860 |
| PMID | 29290969 |
| PMC | PMC5739754 |
| IF | 5.168 |
| 引用数 | 17 |
| リソース情報 | |
| ヒト・動物細胞 | Kato III(RCB2088) NUGC-4(RCB1939) MKN45(RCB1001) MKN74(RCB1002) |